Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.75 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.75 |
| ▸ | ABL1 | P00519 | 8/20 | 0.69 |
| ▸ | KIT | P10721 | 8/20 | 0.69 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.68 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.64 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531087 | 0.92 | ABL1 (0.68) | MAPK14MAPK9ABL1KITDDR2 | |
| SCHEMBL3533757 | 0.92 | MAPK14 (0.74) | MAPK14MAPK9ABL1KITDDR2 | |
| SCHEMBL3534548 | 0.90 | ABL1 (0.64) | MAPK14MAPK9ABL1KITDDR2 | |
| SCHEMBL3532719 | 0.90 | MAPK14 (0.68) | MAPK14MAPK9ABL1KITDDR2 | |
| SCHEMBL3534734 | 0.87 | MAPK14 (0.65) | MAPK14MAPK9ABL1KITDDR2 | |
| SCHEMBL3532357 | 0.86 | MAPK14 (0.63) | MAPK14MAPK9ABL1KITDDR2 | |
| SCHEMBL3528684 | 0.86 | MAPK14 (0.63) | MAPK14MAPK9ABL1KITDDR2 | |
| SCHEMBL3532936 | 0.83 | MAPK14 (0.54) | MAPK14MAPK9ABL1KITDDR2 | |
| SCHEMBL3528535 | 0.82 | MAPK14 (0.66) | MAPK14MAPK9ABL1KITDDR2 | |
| SCHEMBL3536026 | 0.82 | NTRK1 (0.64) | MAPK14MAPK9ABL1KITDDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912998-B1 | PYRAZOLE DERIVATIVES HAVING TYROSINKINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2013-03-06 | — | — | EP | claimed |
| US-20080207647-A1 | Pyrazole Derivatives Having Tyrosine Kinase Activity | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | claimed |
| US-7662827-B2 | Pyrazole derivatives having tyrosine kinase inhibitory activity | MERCK PATENT GMBH (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20080207647-A1 | Pyrazole Derivatives Having Tyrosine Kinase Activity | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207647-A1 | Pyrazole Derivatives Having Tyrosine Kinase Activity | TIE1, FER, ROS1 | MAPK14 592/4885MAPK9 492/4885ABL1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.